Ritlecitinib improves SALT scores in patients with alopecia areata
Click Here to Manage Email Alerts
MILAN — Severity of alopecia areata as well as scalp hair regrowth continued to improve with treatment at 48 weeks in further analysis of data from the ALLEGRO trial, according to a poster presented here.
“Alopecia areata is an autoimmune disease that has an underlying immunoinflammatory pathogenesis and is characterized by nonscarring hair loss ranging from small patches to complete scalp, face and body hair loss,” Ulrike Blume-Peytavi, MD, and colleagues wrote in their presentation at the European Academy of Dermatology and Venereology Congress. “In this post hoc analysis, we assessed responses to ritlecitinib treatment based on predefined SALT [Severity of Alopecia Tool] improvement categories from baseline to week 24 and week 48.”
As Healio previously reported, the ALLEGRO phase 2b/3 trial studied five ritlecitinib doses compared with placebo. Two dosing groups received a 4-week loading dose of 200 mg before 50 mg or 30 mg doses. The other groups received 50 mg, 30 mg or 10 mg. After 24 weeks of treatment, those in the placebo group were switched to active therapy.
Across all ritlecitinib dose regimens tested, a greater proportion of patients achieved SALT 50, SALT 75, SALT 90 or SALT 100 at week 24 compared with placebo, according to the poster, and the proportion of patients with SALT score improvements continued to increase through week 48.
“SALT improvement scores may help facilitate discussion of treatment progress with patients with [alopecia areata],” the authors wrote.
Collapse
Blume-Peytavi U, et al. Poster. Evaluation of response to ritlecitinib (PF-06651600) treatment based on SALT improvement scores in patients with alopecia areata: Post hoc analysis of the ALLEGRO phase 2b/3 study. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 7-10, 2022; Milan.
Read more about
Click Here to Manage Email Alerts